Health Condition 1: L308- Other specified dermatitis
Conditions
Interventions
Intervention1: Azathioprine: Azathioprine 50 mg once a day for initial 2 weeks followed by 2.5mg/kg/day in two divided doses for 12 weeks
Control Intervention1: Mycophenolate mofetil: Mycophenolate mo
Sponsors
Post Graduate Institute of Medical Education and Research Chandigarh
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as chronic actinic dermatitis. 2. Age >18 years.
Exclusion criteria
Exclusion criteria: 1. Patients with hepatic/ renal disease/peptic ulcer disease. 2. Severe anaemia ( 3. Active infectious disease or immune system deficiency including AIDS. 4. Pregnant or lactating women. 5. Significant abnormalities in liver function (serum bilirubin, AST, ALT, and ALP > 1.5 times the upper limit of normal), viral hepatitis or cirrhosis. 6. H/o intolerance/hypersensitivity to azathioprine and/or mycophenolate mofetil.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ·To compare the clinical and functional outcome after 3 months in each group, as assessed by EASI and DLQI. ·To compare the safety and tolerability of each drug by regular evaluation of clinical and biochemical parameters. Timepoint: Week 2, week 4, week 8, week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| · Identification of the clinicodemographic factors predicting clinical outcome in each group.Timepoint: Baseline and week 12 | — |
Countries
India
Contacts
Public ContactSanjeev Handa
Post Graduate Institute of Medical Education and Research
Outcome results
None listed